(Total Views: 622)
Posted On: 08/07/2024 9:58:51 PM
Post# of 153908
Quote:
Seems FDA nixed Agenus' plan for accelerated approval for botensilimab/balstilimab in MSS colorectal cancer.
Quote:
Agenus went all in on the combination of its CTLA-4 blocking antibody botensilimab and PD-1 candidate balstilimab to cut costs last year.
https://www.fiercebiotech.com/biotech/fda-wre...ombination
Why combine 2 drugs when leronlimab does both and more.
(10)
(0)
